Show simple item record

dc.contributor.authorTivey, Ann
dc.contributor.authorShotton, R.
dc.contributor.authorLee, Rebecca J
dc.contributor.authorZhou, Cong
dc.contributor.authorBanfill, Kathryn
dc.contributor.authorHague, Christina
dc.contributor.authorGomes, Fabio
dc.contributor.authorWeaver, Jamie M
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorCooksley, Timothy J
dc.date.accessioned2020-12-08T05:36:27Z
dc.date.available2020-12-08T05:36:27Z
dc.date.issued2020en
dc.identifier.citationTivey A, Shotton R, Lee R, Zhou C, Banfill K, Hague C, et al. 1722P Longitudinal analysis of biochemical and haematological features of cancer patients with COVID-19. Annals of Oncology. 2020;31:S1011-S.en
dc.identifier.doi10.1016/j.annonc.2020.08.1786en
dc.identifier.urihttp://hdl.handle.net/10541/623465
dc.description.abstractBackground: Cancer patients (pts) are at increased risk of severe COVID-19 infection and death. Older pts, men and those with haematological malignancies and receiving anti-tumour therapy within 14 days appear to be at highest risk for poor outcomes. In general populations, severe COVID-19 infection has been associated with neutrophilia, raised lactate dehydrogenase (LDH) and C-reactive protein (CRP). Cancer and its treatment affect many haematological and biochemical parameters.We examined whether COVID-19 infection affected these compared to pts’ baseline parameters by longitudinal tracking. We also investigated whether changes were associated with poor outcome. Methods: Consecutive pts with solid or haematological malignancies presenting with index symptoms and testing positive for SARS-CoV-2 at a tertiary oncology centre were identified following institutional board approval. Clinical and laboratory data were extracted from the pt record. Paired T-tests were used for longitudinal sampling and ANOVA/Chi squared for outcomes. Results: 52 pts tested positive (27 male, 25 female; median age 63). 80.5% had solid cancers, and 19.5% haematological. 31/52 pts were lymphopenic prior to infection. Comparing mean pre-infection counts (6 months-14 days¼PRE) with mean counts from the 5 days following positive test (DURING) lymphocyte counts significantly decreased during infection (p<0.0001). Platelets were significantly reduced DURING vs. PRE COVID-19 (p¼0.0028). 17/52 pts developed transient (median 2 days) neutropenia (<2x109/L) DURING infection (6 pts <1x109/L, 2 pts <0.5x109/L), 8/17 attributed to cancer/cancer therapy, the rest had no underlying cause. 8/17 pts received growth factor support. Reduced lymphocytes/neutrophils/platelets at diagnosis were not associated with oxygen requirement (O2) or death. Different CRP trajectories were observed when comparing pts grouped by discharge/ O2/death. Higher CRP and LDH at diagnosis were associated with admission (p¼0.02 CRP/0.2 LDH), O2 (p¼0.0002 CRP/p<0.01 LDH) and death (p¼0.069 CRP/p¼0.04 LDH). Updated analysis will be presented. Conclusions: Infection with SARS-CoV-2 commonly affects haematological parameters in cancer pts. High CRP and LDH are associated with poor outcomes.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2020.08.1786en
dc.titleLongitudinal analysis of biochemical and haematological features of cancer patients with COVID-19en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-12-08T11:24:23Z


Files in this item

Thumbnail
Name:
Longitudinal.pdf
Size:
83.63Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record